Kinnate Biopharma (KNTE) News

Kinnate Biopharma (KNTE): $12.75

0.14 (+1.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KNTE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter KNTE News Items

KNTE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KNTE News Highlights

  • KNTE's 30 day story count now stands at 3.
  • Over the past 7 days, the trend for KNTE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about KNTE are LEE and LUNG.

Latest KNTE News From Around the Web

Below are the latest news stories about Kinnate Biopharma Inc that investors may wish to consider to help them evaluate KNTE as an investment opportunity.

Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Presentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancerSAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it has been selected to deliver an oral presentation of preclinical dat

Yahoo | February 14, 2022

Gabelli Convertible and Income Securities Fund Declares First Quarter Distribution of $0.12 Per Share

RYE, N.Y., February 09, 2022--The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund") declared a $0.12 per share cash distribution payable on March 24, 2022 to common stock shareholders of record on March 17, 2022.

Yahoo | February 9, 2022

Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. Event: 11th Annual SVB Lee

Yahoo | February 7, 2022

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Presentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutationsSAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the

Yahoo | January 19, 2022

Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248

Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generat

Yahoo | January 18, 2022

Kinnate Biopharma (KNTE) Gets a Buy Rating from Jefferies

Jefferies analyst Roger Song maintained a Buy rating on Kinnate Biopharma (KNTE – Research Report) on January 8 and set a price target of $46.00. The company's shares closed last Friday at $14.86. According to TipRanks.com, Song is ranked 0 out of 5 stars with an average return of -20.5% and a 7.7% success rate. Song covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Inovio Pharmaceuticals, and Aclaris Therapeutics. Kinnate Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $41.67, implying a 180.4% upside from current levels.

Christine Brown on TipRanks | January 10, 2022

Kinnate Biopharma (KNTE) Initiated with a Buy at Leerink Partners

In a report issued on January 7, Andrew Berens from Leerink Partners initiated coverage with a Buy rating on Kinnate Biopharma (KNTE – Research Report). The company's shares closed last Friday at $14.86. According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.8% and a 44.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kinnate Biopharma with a $41.67 average price target, implying a 169.7% upside from current levels.

Brian Anderson on TipRanks | January 9, 2022

Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones

Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first half of 2022 Announces planned initiation of Phase 1 trial of KIN-3248 for first half of 2022 subject to IND clearance by the FDA Updated cash, cash equivalents and investments of approximately $324.9 mill

Yahoo | January 6, 2022

Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...

Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

Yahoo | December 21, 2021

Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings

AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancers Symposium presentation will highlight results from preclinical studies evaluating the company’s lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248 SAN FRANCISCO and SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopha

Yahoo | December 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4884 seconds.